



Test Report Status	Results	Biological Reference Interval Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
DRAWN :	RECEIVED : 13/08/2022 09:06	REPORTED : 13/08/2022 14:17
ACCESSION NO : 4182VH006048	AGE: 41 Years SEX : Male	
PATIENT NAME : MR RATHEESH	R	PATIENT ID : MRRAM1308814182

MEDIWHEEL HEALTH CHECKUP ABOVE 40(M)TMT

CLIENT CODE: CA00010147 CLIENT'S NAME AND ADDRESS: MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI,

SOUTH DELHI 110030

DELHI INDIA

8800465156

*** TREADMILL TEST** TREADMILL TEST REPORT GIVEN DENTAL CHECK UP DENTAL CHECK UP REPORT GIVEN OPTHAL OPTHAL REPORT GIVEN









CLIENT CODE : CA00010147 CLIENT'S NAME AND ADDRESS : MEDIWHEEL ARCOFEMI HEALTHCARE LIMIT F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156		MEDICAL CO TRIVANDRUM KERALA, IND Tel : 93334 9	RE BUILDING, ULLOOR, LLEGE P.O 1, 695011	⁻ C161480
PATIENT NAME : MR RATHEESH R			PATIENT ID : MRRA	M1308814182
ACCESSION NO : 4182VH006048	AGE : 41 Years SEX : Male	9		
DRAWN :	RECEIVED : 13/08/2022 09:0	6	REPORTED : 13/08/2022 14:1	7
REFERRING DOCTOR : SELF			CLIENT PATIENT ID :	
Test Report Status	Results			Units
MEDIWHEEL HEALTH CHECKUP AB				
* SERUM BLOOD UREA NITROGEN	13		6 - 20	ma/dl
BLOOD UREA NITROGEN * BUN/CREAT RATIO	15		0 - 20	mg/dL
BUN/CREAT RATIO	13.7			
CREATININE, SERUM	15.7			
CREATININE	0.95		0.9 - 1.3	mg/dL
* GLUCOSE, POST-PRANDIAL, PLA				
GLUCOSE, POST-PRANDIAL, PLASMA	153	High	Diabetes Mellitus : > or = 200 mg/dL. Impaired Glucose tolerance/ Prediabetes : 140 to 199 mg/dl Hypoglycemia : < 55 mg/dL.	mg/dL L.
GLUCOSE, FASTING, PLASMA				
GLUCOSE, FASTING, PLASMA	118		Diabetes Mellitus : > or = 126 mg/dL. Impaired fasting Glucose/ Prediabetes : 101 to 125 mg/dl Hypoglycemia : < 55 mg/dL.	
* GLYCOSYLATED HEMOGLOBIN, E	EDTA WHOLE BLOOD			
GLYCOSYLATED HEMOGLOBIN (HBA10	C) 5.6		Normal : 4.0 - 5.6 %. Non-diabetic level : < 5.7%. More stringent goal : < 6.5 %. General goal : < 7%. Less stringent goal : < 8%. Glycemic targets in CKD :- If eGFR > 60 : < 7%. If eGFR < 60 : 7 - 8.5%.	%
MEAN PLASMA GLUCOSE	114.0			mg/dL
* CORONARY RISK PROFILE (LIPI	D PROFILE), SERUM			
CHOLESTEROL	236	High	Desirable cholesterol level < 200 Borderline high cholesterol 200 - 239 High cholesterol > / = 240	mg/dL
TRIGLYCERIDES	155	High	Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL









REPORTED :

CLIENT CODE : CA00010147 CLIENT'S NAME AND ADDRESS : MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

PATIENT NAME : MR RATHEESH R

REFERRING DOCTOR : SELF

1_

PATIENT ID : MRRAM1308814182

ACCESSION NO :	4182VH006048	AGE :	41 Yea	ars	SEX : Male
DRAWN :		RECE	IVED :	13/08	/2022 09:06

CLIENT PATIENT ID :

13/08/2022 14:17

Test Report Status	Results			Units
HDL CHOLESTEROL	38	Low	Low HDL cholesterol < 40	mg/dL
DIRECT LDL CHOLESTEROL	170	High	High HDL cholesterol > / = 60 Adult Optimal : < 100	mg/dL
			Near optimal : 100 - 129 Borderline high : 130 - 159 High : 160 - 189 Very high : > or = 190	
NON HDL CHOLESTEROL	198	High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219	mg/dL
CHOL/HDL RATIO	6.2	High	Very high: > or = 220 3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	4.5	High	 h 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk > 6.0 High Risk 	
VERY LOW DENSITY LIPOPROTEIN	31.0		Desirable value : 10 - 35	mg/dL
* LIVER FUNCTION TEST WITH GGT				
BILIRUBIN, TOTAL	1.23	High	< 1.1	mg/dL
BILIRUBIN, DIRECT	0.36	High	< or = 0.30	mg/dL
BILIRUBIN, INDIRECT	0.87	High	0.00 - 0.60	mg/dL
TOTAL PROTEIN	7.2		6.4 - 8.3	g/dL
ALBUMIN	5.0		3.5 - 5.2	g/dL
GLOBULIN	2.2		2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
ALBUMIN/GLOBULIN RATIO	2.3	High	1.00 - 2.00	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	25		< 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	49	High	< 41	U/L
ALKALINE PHOSPHATASE	99		40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	43		8 - 61	U/L
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN	7.2		6.6 - 8.7	g/dL
URIC ACID, SERUM				









CLIENT CODE: CA00010147 CLIENT'S NAME AND ADDRESS: MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156

PATIENT NAME : MR RATHEESH R

ACCESSION NO :	4182VH006048	AGE :	41 Years	SEX : Male
DRAWN :		RECE	IVED : 13,	/08/2022 09:06

REFERRING DOCTOR : SELF

Test Report Status	Results		Units
URIC ACID	6.2	3.4 - 7.0	mg/dL
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD			
ABO GROUP	TYPE O		
RH TYPE	POSITIVE		
* BLOOD COUNTS			
HEMOGLOBIN	14.5	13.0 - 17.0	g/dL
RED BLOOD CELL COUNT	4.79	4.5 - 5.5	mil/µL
WHITE BLOOD CELL COUNT	6.82	4.0 - 10.0	thou/µL
PLATELET COUNT	286	150 - 410	thou/µL
* RBC AND PLATELET INDICES			
HEMATOCRIT	44.3	40 - 50	%
MEAN CORPUSCULAR VOL	92.6	83 - 101	fL
MEAN CORPUSCULAR HGB.	30.3	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION	32.7	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH	12.8	11.6 - 14.0	%
MEAN PLATELET VOLUME	8.6	6.8 - 10.9	fL
* WBC DIFFERENTIAL COUNT - NLR			
SEGMENTED NEUTROPHILS	49	40 - 80	%
ABSOLUTE NEUTROPHIL COUNT	3.34	2.0 - 7.0	thou/µL
LYMPHOCYTES	38	20 - 40	%
ABSOLUTE LYMPHOCYTE COUNT	2.59	1 - 3	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.3		
EOSINOPHILS	6	1 - 6	%
ABSOLUTE EOSINOPHIL COUNT	0.41	0.02 - 0.50	thou/µL
MONOCYTES	7	2 - 10	%
ABSOLUTE MONOCYTE COUNT	0.48	0.20 - 1.00	thou/µL
BASOPHILS	0	0 - 1	%
ABSOLUTE BASOPHIL COUNT	0.00		thou/µL
* ERYTHRO SEDIMENTATION RATE, BLOOD			
SEDIMENTATION RATE (ESR)	12	0 - 14	mm at 1 hr
STOOL: OVA & PARASITE	RESULT PENDING		
* SUGAR URINE - POST PRANDIAL			
SUGAR URINE - POST PRANDIAL	NOT DETECTED	NOT DETECTED	





REPORTED : 13/08/2022 14:17

MRRAM1308814182

CLIENT PATIENT ID :

PATIENT ID :





CLIENT CODE : CA00010147 CLIENT'S NAME AND ADDRESS : MEDIWHEEL ARCOFEMI HEALTHCARE LIMIT F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA 8800465156	ED A	Cert. No. MC-2812 IRC SRL DIAGNOSTICS TER SQUARE BUILDING, ULLOOR, DICAL COLLEGE P.O IVANDRUM, 695011 RALA, INDIA : 93334 93334, Fax : CIN - U85190MH2006PTC161480 hail : customercare.ddrc@srl.in		
PATIENT NAME : MR RATHEESH R		PATIENT ID :	MRRAM1308814182	
ACCESSION NO : 4182VH006048	AGE : 41 Years SEX : Male			
DRAWN :	RECEIVED : 13/08/2022 09:06	REPORTED : 13/08/20	22 14:17	
REFERRING DOCTOR : SELF		CLIENT PATIENT ID):	
Test Report Status	Results		Units	
URINALYSIS				
COLOR	YELLOWISH			
APPEARANCE	CLEAR			
PH	6.0			
SPECIFIC GRAVITY	1.023			
GLUCOSE	NEGATIVE	NOT DETECTED		
PROTEIN	NEGATIVE	NOT DETECTED		
KETONES	NEGATIVE	NOT DETECTED		
BLOOD	NEGATIVE	NOT DETECTED		
BILIRUBIN	NOT DETECTED	NOT DETECTED		
UROBILINOGEN	NORMAL	NORMAL		
NITRITE	NEGATIVE	NOT DETECTED		
WBC	0-1	0-5	/HPF	
EPITHELIAL CELLS	0-1	0-5	/HPF	
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF	
CASTS	NEGATIVE			
CRYSTALS	NEGATIVE			
REMARKS	NIL			
PROSTATE SPECIFIC ANTIGEN, SE	RUM			
PROSTATE SPECIFIC ANTIGEN	0.430	< 0.01 - 4.00	ng/mL	
* THYROID PANEL, SERUM				
Т3	95.46	60.0 - 181.0	ng/dL	
Τ4	7.80	4.5 - 10.9	µg/dl	
TSH 3RD GENERATION	2.140	0.550 - 4.780	µIU/mL	
Interpretation(s) SERUM BLOOD UREA NITROGEN- Causes of Increased levels Pre renal • High protein diet, Increased protein catabolism, • Renal Failure Post Renal • Malignancy, Nephrolithiasis, Prostatism	GI haemorrhage, Cortisol, Dehydration,	CHF Renal		

Causes of decreased levels • Liver disease • SIADH. CREATININE, SERUM-Higher than normal level may be due to: • Blockage in the urinary tract









Test Report Status	Results		Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID	:
DRAWN :	RECEIVED : 13/08/2022 09:06	REPORTED : 13/08/202	22 14:17
ACCESSION NO : 4182VH006048	AGE: 41 Years SEX: Male		
PATIENT NAME : MR RATHEESH	R	PATIENT ID :	MRRAM1308814182
8800465156		customercare.durc@sh.m	

• Kidney problems, such as kidney damage or failure, infection, or reduced blood flow

Loss of body fluid (dehydration)
Muscle problems, such as breakdown of muscle fibers

CLIENT CODE: CA00010147

CLIENT'S NAME AND ADDRESS :

F701A, LADO SARAI, NEW DELHI,

SOUTH DELHI, DELHI,

SOUTH DELHI 110030

DELHI INDIA

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

• Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

Mvasthenia Gravis

Muscular dystrophy

ADA Guidelines for 2hr post prandial glucose levels is only after ingestion of 75grams of glucose in 300 ml water, over a period of 5 minutes.

GLUCOSE, FASTING, PLASMA ADA 2012 guidelines for adults as follows:

Pre-diabetics: 100 - 125 mg/dL Diabetic: > or = 126 mg/dL

(Ref: Tietz 4th Edition & ADA 2012 Guidelines) GLYCOSYLATED HEMOGLOBIN, EDTA WHOLE BLOOD-

Glycosylated hemoglobin (GHb) has been firmly established as an index of long-term blood glucose concentrations and as a measure of the risk for the development of complications in patients with diabetes mellitus. Formation of GHb is essentially irreversible, and the concentration in the blood depends on both the life span of the red blood cell (average 120 days) and the blood glucose concentration. Because the rate of formation of GHb is directly proportional to the concentration of glucose in the blood,

the GHb concentration represents the integrated values for glucose over the preceding 6-8 weeks. Any condition that alters the life span of the red blood cells has the potential to alter the GHb level. Samples from patients with hemolytic anemias will exhibit decreased glycated hemoglobin values due to the shortened life span of the red cells. This effect will depend upon the severity of the anemia. Samples from patients with polycythemia

or post-splenectomy may exhibit increased glycated hemoglobin values due to a somewhat longer life span of the red cells. Glycosylated hemoglobins results from patients with HbSS, HbCC, and HbSC and HbD must be interpreted with caution, given the pathological processes, including anemia, increased red cell turnover, transfusion requirements, that adversely impact HbA1c as a marker of long-term glycemic control. In these conditions, alternative forms of testing such as glycated serum protein (fructosamine) should be considered.

Targets should be individualized; More or less stringent glycemic goals may be appropriate for individual patients. Goals should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions, known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations."

References

1. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burtis, Edward R.Ashwood, David E Bruns, 4th Edition, Elsevier publication, 2006, 879-884

2. Forsham PH. Diabetes Mellitus: A rational plan for management. Postgrad Med 1982, 71,139-154.

2. Mayer TK, Freedman ZR: Protein glycosylation in Diabetes Mellitus: A review of laboratory measurements and their clinical utility. Clin Chim Acta 1983, 127, 147-184. CORONARY RISK PROFILE (LIPID PROFILE), SERUM-

Serum cholesterol is a blood test that can provide valuable information for the risk of coronary artery disease This test can help determine your risk of the build up of plaques in your arteries that can lead to narrowed or blocked arteries throughout your body (atherosclerosis). High cholesterol levels usually don't cause any signs or symptoms, so a cholesterol test is an important tool. High cholesterol levels often are a significant risk factor for heart disease and important for diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.

Serum Triglyceride are a type of fat in the blood. When you eat, your body converts any calories it doesn't need into triglycerides, which are stored in fat cells. High triglyceride levels are associated with several factors, including being overweight, eating too many sweets or drinking too much alcohol, smoking, being sedentary, or having diabetes with elevated blood sugar levels. Analysis has proven useful in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, and various endocrine disorders. In conjunction with high density lipoprotein and total serum cholesterol, a triglyceride determination provides valuable information for the assessment of coronary heart disease risk. It is done in fasting state.

High-density lipoprotein (HDL) cholesterol. This is sometimes called the ""good" cholesterol because it helps carry away LDL cholesterol, thus keeping arteries open and blood flowing more freely. HDL cholesterol is inversely related to the risk for cardiovascular disease. It increases following regular exercise, moderate alcohol consumption and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery disease, individuals with triglyceride levels between 70 and 140 mg/dL, as well as individuals with a diet high in trans-fat or carbohydrates. Elevated sdLDL levels are associated with metabolic syndrome and an 'atherogenic lipoprotein profile', and are a strong, independent predictor of cardiovascular disease. Elevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also been implicated, as has genetic predisposition. Measurement of sdLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels will reduce the risk of CVD and MI.

Non HDL Cholesterol - Adult treatment panel ATP III suggested the addition of Non-HDL Cholesterol as an indicator of all atherogenic lipoproteins (mainly LDL and VLDL). NICE guidelines recommend Non-HDL Cholesterol measurement before initiating lipid lowering therapy. It has also been shown to be a better marker of risk in both primary and secondary prevention studies.

Recommendations:

Results of Lipids should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.





Scan to View Details





Test Report Status	Results	Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
DRAWN :	RECEIVED : 13/08/2022 09:06	REPORTED : 13/08/2022 14:17
ACCESSION NO : 4182VH006048	AGE: 41 Years SEX : Male	
PATIENT NAME : MR RATHEESH	R	PATIENT ID : MRRAM1308814182

NON FASTING LIPID PROFILE includes Total Cholesterol, HDL Cholesterol and calculated non-HDL Cholesterol. It does not include triglycerides and may be best used in patients for whom fasting is difficult. TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum.. Protein in the plasma is made up of albumin and alobulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. URIC ACID, SERUM-

Causes of Increased levels Dietarv • High Protein Intake.

CLIENT CODE: CA00010147

CLIENT'S NAME AND ADDRESS :

F701A, LADO SARAI, NEW DELHI,

SOUTH DELHI, DELHI,

SOUTH DELHI 110030

DELHI INDIA

8800465156

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

- Prolonged Fasting, Rapid weight loss. Gout Lesch nyhan syndrome.
- Type 2 DM. Metabolic syndrome.

Causes of decreased levels

- Low Zinc Intake • OCP's
- Multiple Sclerosis

Nutritional tips to manage increased Uric acid levels

- Drink plenty of fluidsLimit animal proteins

High Fibre foodsVit C Intake

Antioxidant rich foods
 ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods. BLOOD COUNTS-

The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-

The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

WBC DIFFERENTIAL COURT - NLR-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tends of the severe of the sev show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504

EXPENSIVE and predictive of each of the second seco and when there are abnormalities of the red cells such as poikilocytosis, spherocytosis or sickle cells.

Reference :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition
2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin
3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th Edition"
SUGAR URINE - POST PRANDIAL-METHOD: DIPSTICK/BENEDICT'S TEST
URINALYSIS-Routine urine analysis assists in screening and diagnosis of various metabolic, urological, kidney and liver disorders
Pratoins Televated proteins can also be an oarthy sign of kidney diagnosis of various metabolic, urological, kidney and liver disorders
Pratoins Televated proteins can also be an oarthy sign of kidney diagnosis of various metabolic, urological, kidney and liver disorders

Protein: Elevated proteins can be an early sign of kidney disease. Urinary protein excretion can also be temporarily elevated by strenuous exercise, orthostatic proteinuria, dehydration, urinary tract infections and acute illness with fever

Glucose: Uncontrolled diabetes mellitus can lead to presence of glucose in urine. Other causes include pregnancy, hormonal disturbances, liver disease and certain









PATIENT NAME : MR RATHEESH F	R	PATIENT ID : MRRAM1308814182
ACCESSION NO : 4182VH006048	AGE : 41 Years SEX : Male	
DRAWN :	RECEIVED : 13/08/2022 09:06	REPORTED : 13/08/2022 14:17
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
Test Report Status	Results	Units

medications.

Ketones: Uncontrolled diabetes mellitus can lead to presence of ketones in urine. Ketones can also be seen in starvation, frequent vomiting, pregnancy and strenuous exercise.

Blood: Occult blood can occur in urine as intact erythrocytes or haemoglobin, which can occur in various urological, nephrological and bleeding disorders. Leukocytes: An increase in leukocytes is an indication of inflammation in urinary tract or kidneys. Most common cause is bacterial urinary tract infection.

Nitrite: Many bacteria give positive results when their number is high. Nitrite concentration during infection increases with length of time the urine specimen is retained in bladder prior to collection. pH: The kidneys play an important role in maintaining acid base balance of the body. Conditions of the body producing acidosis/ alkalosis or ingestion of certain type of food

can affect the pH of urine. Specific gravity: Specific gravity gives an indication of how concentrated the urine is. Increased specific gravity is seen in conditions like dehydration, glycosuria and

proteinuria while decreased specific gravity is seen in excessive fluid intake, renal failure and diabetes insipidus. Bilirubin: In certain liver diseases such as biliary obstruction or hepatitis, bilirubin gets excreted in urine. Urobilinogen: Positive results are seen in liver diseases like hepatitis and cirrhosis and in cases of hemolytic anemia

CLIENT CODE: CA00010147 CLIENT'S NAME AND ADDRESS: MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI,

SOUTH DELHI, DELHI,

SOUTH DELHI 110030

DELHI INDIA

8800465156

PROSTATE SPECIFIC ANTIGEN, SERUM-Prostate Specific Antigen (PSA) is a single-chain glycoprotein normally found in the cytoplasm of the epithelial cells lining the acini and ducts of the prostate gland. PSA is detected in the serum of males with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis. PSA is not detected (or detected at very low levels) in the serum of males without prostate tissue (because of radical prostatectomy or cystoprostatectomy) or in the serum of most females.

The fact that PSA is unique to prostate tissue makes it a suitable marker for monitoring men with cancer of the prostate. PSA is also useful for determining possible recurrence after therapy when used in conjunction with other diagnostic indices. PSA levels increase in men with cancer of the prostate. After radical prostatectomy PSA levels routinely fail to a very low level, which may not be seen in patients undergoing radiation therapy. Monitoring PSA levels appears to be useful in detecting residual disease and early recurrence of tumor. Therefore, serial PSA levels can help determine the success of prostatectomy and the need for further treatment, such as radiation, endocrine or chemotherapy and in the monitoring of the effectiveness of therapy.

PSA levels should not be interpreted as absolute evidence of the presence or the absence of malignant disease. Before treatment, patients with confirmed prostate carcinoma frequently have levels of PSA within the range observed in healthy individuals. Elevated levels of PSA can be observed in the patients with nonmalignant diseases. Measurement of PSA should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation. The concentration of total PSA in a given specimen determined with assays from different manufacturers can vary due to differences in assay methods, calibration, and reagent specificity. Values obtained with different assay method cannot be used interchangeably.

Heterophilic antibodies in human serum can react with reagent immunoglobulins, interfering with in vitro immunoassays. Patients routinely exposed to animals or to animal serum products can be prone to this interference and anomalous values may be observed. Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA levels persisting upto 3 weeks. THYROID PANEL, SERUM-

Trilodo HARLE, Schonne T3, is a thyroid hormone. It affects almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate. Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Thyroxine T4, Thyroxine's principal function is to stimulate the metabolism of all cells and tissues in the body. Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3

Levels in	TOTAL T4	TSH3G	TOTAL T3
Pregnancy	(µg/dL)	(µIU/mL)	(ng/dL)
First Trimester	6.6 - 12.4	0.1 - 2.5	81 - 190
2nd Trimester	6.6 - 15.5	0.2 - 3.0	100 - 260
3rd Trimester	6.6 - 15.5	0.3 - 3.0	100 - 260
Polow montioned	are the quidelines	for any related referer	nco ranges for T2

Below mentioned are the guidelines for age related reference ranges for T3 and T4. T^{2}

15	14	
(ng/dL)	(µg/dL)	
New Born: 75 - 260	1-3 day: 8.2 - 19.9	
	1 Week: 6.0 - 15.9	

NOTE: TSH concentrations in apparently normal euthyroid subjects are known to be highly skewed, with a strong tailed distribution towards higher TSH values. This is well documented in the pediatric population including the infant age group. Kindly note: Method specific reference ranges are appearing on the report under biological reference range.

Burtis C.A., Ashwood E. R. Bruns D.E. Teitz textbook of Clinical Chemistry and Molecular Diagnostics, 4th Edition.
 Gowenlock A.H. Varley's Practical Clinical Biochemistry, 6th Edition.

3. Behrman R.E. Kilegman R.M., Jenson H. B. Nelson Text Book of Pediatrics, 17th Edition





Page 8 Of 9

Scan to View Report





Test Report Status	Results	Units
REFERRING DOCTOR : SELF		CLIENT PATIENT ID :
DRAWN :	RECEIVED : 13/08/2022 09:06	REPORTED : 13/08/2022 14:17
ACCESSION NO : 4182VH006048	AGE: 41 Years SEX: Male	
PATIENT NAME : MR RATHEESH	R	PATIENT ID : MRRAM1308814182
8800465156	Lindi .	

MEDIWHEEL HEALTH CHECKUP ABOVE 40(M)TMT

* ECG WITH REPORT

REPORT REPORT GIVEN * USG ABDOMEN AND PELVIS

CLIENT CODE: CA00010147 CLIENT'S NAME AND ADDRESS: MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI,

SOUTH DELHI, DELHI,

SOUTH DELHI 110030

DELHI INDIA

REPORT REPORT GIVEN * CHEST X-RAY WITH REPORT

REPORT REPORT GIVEN

> **End Of Report** Please visit www.srlworld.com for related Test Information for this accession TEST MARKED WITH '*' ARE OUTSIDE THE NABL ACCREDITED SCOPE OF THE LABORATORY.

Ralunaun

BABU K MATHEW HOD -BIOCHEMISTRY

hal

DR.VAISHALI RAJAN HOD - HAEMATOLOGY

PADMANABHAN NAIR HOD - HORMONES





COLOUR DOPPLER ULTRASOUND SCANNING ECHO

DDRC SRL Diagnostic Services

RADIOLOGY DIVISION

Acc no:4182VH006048	Name: Mr. Ratheesh R	Age: 41 y	Sex: Male	
•			Sex. Male	Date: 13.08.2
	US SCAN WHOLE AL	PROMEN		_

JS SCAN WHOLE ABDOMEN

LIVER is enlarged in size (~16.3 cm). Margins are regular. Hepatic parenchyma shows increased echogenicity. No focal lesions seen. No dilatation of intrahepatic biliary radicles. CBD is not dilated. Portal vein is normal in caliber (9.9 mm).

GALL BLADDER is partially distended and grossly normal. No pericholecystic fluid seen.

SPLEEN is normal in size (9.4 cm) and parenchymal echotexture. No focal lesion seen.

PANCREAS Obscured by bowel air.

RIGHT KIDNEY is normal in size (11.3 x 4.8 cm) and shows normal parenchymal echotexture. Cortico medullary differentiation is maintained. Parenchymal thickness is normal. No echogenic focus with shadowing suggestive of renal calculi seen. No dilatation of pelvicalyceal system seen. Ureter is not dilated. Perinephric spaces are normal.

LEFT KIDNEY is normal in size (12.6 x 5.2 cm) and shows normal parenchymal echotexture. Cortico medullary differentiation is maintained. Parenchymal thickness is normal. No echogenic focus with shadowing suggestive of renal calculi seen. No dilatation of pelvicalyceal system seen. Ureter is not dilated. Perinephric spaces are normal.

PARAAORTIC AREA Obscured by bowel air.

URINARY BLADDER is partially distended, normal in wall thickness, lumen clear.

PROSTATE is normal in size (vol - 16.6cc) .

No ascites or pleural effusion.

Gaseous distension of bowel loops noted.

CONCLUSION:-

Hepatomegaly with grade III fatty changes - suggest LFT correlation.

Dr. Nisha Unni MD , DNB (RD) Consultant radiologist.

Thanks, your feedback will be appreciated. (Please bring relevant investigation reports during all visits). Because of technical and technological limitations complete accuracy cannot be assured on imaging. Suggested correlation with clinical findings and other relevant investigations consultations, and if required repeat imaging recommended in the event of controversities.

DDRC SRL Diagnostics Private Limited

Aster Square, Medical College P.O., Trivandrum - 695 011. Ph: 0471 - 2551125. e-mail: info@ddrcsrl.com, web: www.ddrcsrl.com Corp. Office: DDRC SRL Tower, G-131, Panampilly Nagar, Ernakulam, Kerala - 682 036. Web: www.ddrcsrl.com VP8805569-22-08-13-38

RATHEESH

APTHERE * THE OWNER OF THE OWNER OWN



















Page 1 of 1

42-150A







DDRC SRL

Patient Details	Date: 13-Aug-22	Time: 11:19:34 AM	
Name: RATHEESH R	ID: 4182VH006048		
Age: 41 y	Sex: M	Height: 164 cms	Weight: 106 Kgs
Clinical History: NIL			


Medications: NIL


Test Details


Protocol:	Bruce	Pr.MHR:	179 bpm	THR: 161 (90 9	% of Pr.MHR) bpm
Total Exec	. Time: 9 m 28 s	Max. HR:	152 (85% of Pr.MHR)bpm	Max. Mets: 1	3.50
Max. BP:	180 / 90 mmHg	Max. BP	KHR: 27360 mmHg/min	Min. BP x HR:	7470 mmHg/min
Test Termi	ination Criteria: THR AT	TAINED			

Protocol Details

Stage Name	Stage Time	Mets	Speed (mph)	Grade (%)	Heart Rate (bpm)	Max. BP (mm/Hg)	Max. ST Level (mm)	Max. ST Slope (mV/s)
	(min : sec)							
Supine	2:12	1.0	0	0	83	140/90	-1.06 aVR	4.25 II
Standing	0:2	1.0	0	0	83	140/90	-0.85 aVR	4.25 II
Hyperventilation	0:22	1.0	0	0	87	140/90	-1.06 aVR	4.60 II
1	3:0	4.6	1.7	10	117	150/90	-1.06 aVR	5.66 II
2	3:0	7.0	2.5	12	129	160/90	-1.70 III	5.66 II
3	3:0	10.2	3.4	14	152	180/90	-2.34 III	5.66 V4
Peak Ex	0:28	13.5	4.2	16	137	180 / 90	-2.34 III	5.66 V4
Recovery(1)	1:0	1.8	1	0	129	170/90	-4.67 aVR	-5.66 aVR
Recovery(2)	1:0	1.0	0	0	113	150/90	-4.67 aVR	5.66 II
Recovery(3)	1:0	1.0	0	0	103	150/90	-2.12 aVR	5.66 II
Recovery(4)	1:0	1.0	0	0	103	140/90	-0.85 aVR	4.25
Recovery(5)	0:12	1.0	0	0	102	140/90	-0.64 aVR	3.18







Linked Median

CALICUT. COCHIN, TRIVANDRUM, KOTTAYAM, SRL DIAGNOSTICS (P) LTD. DDRC




Chart Speed: 25 mm/sec Schiller Spandan V 4.7

Filter: 35 Hz Iso = R - 60 ms J = R + 60 ms Mains Filt: ON Post J = J + 60 ms Amp: 5 mm Linked Median

n dian

CALICUT. COCHIN, SRL DIAGNOSTICS (P) LTD. TRIVANDRUM, KOTTAYAM, DDRC





Chart Speed: 25 mm/sec Schiller Spandan V 4.7


Filter: 35 Hz Iso = R - 60 ms J = R + 60 ms

Mains Filt: ON Post J = J + 60 ms Amp: 5 mm Linked Median


CALICUT COCHIN. TRIVANDRUM, KOTTAYAM, SRL DIAGNOSTICS (P) LTD. DDRC




TRIVANDRUM, KOTTAYAM, COCHIN, CALICUT, SRL DIAGNOSTICS (P) LTD.




CALICUT. COCHIN. KOTTAYAM TRIVANDRUM. 3 DIAGNOSTICS SRL DDRC




CALICUT COCHIN, TRIVANDRUM, KOTTAYAM, (P) LTD.



CALICUT, COCHIN. KOTTAYAM, TRIVANDRUM, LTD. 6




CALICUT, COCHIN. TRIVANDRUM, KOTTAYAM, SRL DIAGNOSTICS (P) LTD. DDRC




CALICUT, COCHIN, KOTTAYAM. DR. **NIV** -LTD. â DIAGNOSTICS SRL


DDRC



COCHIN, CALICUT, KOTTAYAM. TRIVANDRUM. (P) LTD. SRL DIAGNOSTICS DDRC




(P) LTD. TRIVANDRUM, KOTTAYAM, COCHIN, CALICUT, DIAGNOSTICS SRL DDRC




COCHIN, CALICUT, (P) LTD. TRIVANDRUM, KOTTAYAM, DIAGNOSTICS SRL

DDRCS



(P) LTD. TRIVANDRUM, KOTTAYAM, COCHIN, CALICUT, DDRC SRL DIAGNOSTICS



TRIVANDRUM, KOTTAYAM, COCHIN, CALICUT, (P) LTD. DDRC SRL DIAGNOSTICS